Rituximab leads to early elimination of circulating CD20(+) T and B lymphocytes in patients with iTTP despite ongoing TPEx

How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood. In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20(+) B and T cells in 24 hours for at least 1 week.

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Carden, Marcus A., Gaddh, Manila, Hoskote, Abhinav, Brown, Michael, Merrill, Virginia, Stowell, Sean R., Chandrakasan, Shanmuganathan, Antun, Ana, Kudchadkar, Ragini, Kotanchiyev, Sarah, Jaye, David L., Bodó, Imre
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Exceptional Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013265/
https://ncbi.nlm.nih.gov/pubmed/32027742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001148
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados